My thoughts on #SOLIDARITY results thus far
Strengths:
Huge size, high power n=11,266
Objective endpoint
Highly generalisable (405 hospitals, 30 countries, all 6 WHO regions).
Groups well matched.
High compliance with protocol.
Not sponsored by company with a material interest

Limitations 1:
Eligibility criteria – unknown duration of symptoms pre-rando
1ry endpoint – Listed as *in-hospital* mortality, but all analyses use *estimated 28-day mortality*
Subgroups crude but pragmatic (ventilated or not). Ironically, did not use WHO ordinal scale!

Limitations 2:
Time to recovery not measured (LOS was, but artefactually increased for Remdes due to planned 10-day course)
No pre-specified sample size or stopping rules.
Unclear what the decision to analyse now was based on
Only 8% ventilated, so can’t apply to severe

Overall thoughts:
A huge achievement, fantastic co-operative endeavour
Remdesevir all combined trials: possible small benefit on time to recovery in non-ventilated patients but any mortality benefit extremely unlikely
HCQ, Lopinavir - dead
IFN - Probably dead (await ACTT-3)